James Onder and OnderLaw have now won $127 million in baby powder cancer lawsuits with a $55 million verdict on May 2 and $72 million verdict in February
St. Louis, Missouri (May 3, 2016) – A second St. Louis jury found for the plaintiff in a Johnson & Johnson products liability lawsuit regarding the company’s Johnson’s Baby Powder and Show to Shower Body Powder and allegations that use of these products for feminine hygiene may lead to ovarian cancer. This is the third such lawsuit against Johnson & Johnson over talcum powder and ovarian cancer, all of which have resulted in losses for Johnson & Johnson.
The second Johnson’s Baby Powder cancer lawsuit, GLORIA RISTESUND, ET AL. vs. JOHNSON & JOHNSON, ET AL., Cause No. 1422-CC09012-01, involved a 62- year old South Dakota woman who was diagnosed with ovarian cancer in 2011, underwent a hysterectomy as part of the cancer treatment and is now in remission. Despite her treatment having a successful resolution and having other risk factors for ovarian cancer, the jury still found for Ristesund and awarded her $5 million as compensation and an additional $50 million in punitive damages. The trial lasted just over three weeks.
Millions of women have used Johnson & Johnson’s talcum powder products for feminine hygiene. According to the American Cancer Society, approximately 22,280 women will be diagnosed with ovarian cancer in 2016 and about 14,240 will die of ovarian cancer this year. Ovarian cancer represents only 3% of all cancers in women, but causes more deaths than any other cancer of the female reproductive system.
There are currently more than 1,200 other talcum powder ovarian cancer lawsuits pending throughout the US with dozens of women and families coming forward every single day. Unfortunately, many consumers simply do not believe that such an innocuous product can lead to cancer. However, when presented with the evidence, which included internal corporate documents, every jury that has had a chance to review the proof has concluded that talcum powder products when used for adult feminine hygiene not only led to the plaintiffs’ ovarian cancer, but that Johnson & Johnson was full aware of these risks and instead of warning consumers, the company placed its own profits ahead of the safety of its customers.